UNLABELLED: To determine the cytogenetic and genotoxic risk associated with therapeutic exposure to 131I (3.7 GBq) in 50 patients with differentiated thyroid carcinoma, we estimated the dosimetric index that reflects the dose to the circulating lymphocytes on Day 4 and at several time intervals after exposure over a period of 2 yr. METHODS: Chromosomal aberrations were scored in peripheral lymphocytes obtained before and then 4 days, 3 mo, 6 mo, 1 yr and 2 yr after the first administration of 3.7 GBq 131I according to two methods: conventional cytogenetics and chromosome 4 painting. RESULTS: The dosimetric index was 0.52 Gy on Day 4, 0.49 Gy at 3 mo, 0.45 Gy at 6 mo, 0.44 Gy at 1 yr and 0.42 Gy at 2 yr by conventional cytogenetics and 0.47 Gy on Day 4, 0.45 Gy at 3 mo, 0.44 Gy at 6 mo, 0.43 Gy at 1 yr and 0.42 Gy at 2 yr by chromosome 4 painting. We found a decrease in the frequency of chromosomal aberrations between Day 4 and 3 mo after exposure. This may be due to the decrease of lymphocyte counts shortly after 131I administration, which will recover later on. In contrast, the number of anomalies remained constant starting 3 mo after 131I administration. CONCLUSION: These techniques permit retrospective biological dosimetry for up to 2 yr after therapeutic exposure to 131I.
UNLABELLED: To determine the cytogenetic and genotoxic risk associated with therapeutic exposure to 131I (3.7 GBq) in 50 patients with differentiated thyroid carcinoma, we estimated the dosimetric index that reflects the dose to the circulating lymphocytes on Day 4 and at several time intervals after exposure over a period of 2 yr. METHODS: Chromosomal aberrations were scored in peripheral lymphocytes obtained before and then 4 days, 3 mo, 6 mo, 1 yr and 2 yr after the first administration of 3.7 GBq131I according to two methods: conventional cytogenetics and chromosome 4 painting. RESULTS: The dosimetric index was 0.52 Gy on Day 4, 0.49 Gy at 3 mo, 0.45 Gy at 6 mo, 0.44 Gy at 1 yr and 0.42 Gy at 2 yr by conventional cytogenetics and 0.47 Gy on Day 4, 0.45 Gy at 3 mo, 0.44 Gy at 6 mo, 0.43 Gy at 1 yr and 0.42 Gy at 2 yr by chromosome 4 painting. We found a decrease in the frequency of chromosomal aberrations between Day 4 and 3 mo after exposure. This may be due to the decrease of lymphocyte counts shortly after 131I administration, which will recover later on. In contrast, the number of anomalies remained constant starting 3 mo after 131I administration. CONCLUSION: These techniques permit retrospective biological dosimetry for up to 2 yr after therapeutic exposure to 131I.
Authors: Gordon K Livingston; Igor K Khvostunov; Eric Gregoire; Joan-Francesc Barquinero; Lin Shi; Satoshi Tashiro Journal: Radiat Environ Biophys Date: 2016-03-25 Impact factor: 1.925
Authors: Márcia Augusta da Silva; Flávia Gomes Silva Valgôde; Júlia Armiliato Gonzalez; Hélio Yoriyaz; Maria Inês Calil Cury Guimarães; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki Journal: Radiat Environ Biophys Date: 2016-03-24 Impact factor: 1.925
Authors: Igor K Khvostunov; Vladimir A Saenko; Valeri Krylov; Andrei Rodichev; Shunichi Yamashita Journal: Radiat Environ Biophys Date: 2017-05-19 Impact factor: 1.925
Authors: D Violot; R M'Kacher; E Adjadj; J Dossou; F de Vathaire; C Parmentier Journal: Eur J Nucl Med Mol Imaging Date: 2004-09-23 Impact factor: 9.236
Authors: Márcia Augusta da Silva; Maria Inês Calil Cury Guimarães; Hélio Yoriyaz; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki Journal: Radiat Environ Biophys Date: 2008-08-19 Impact factor: 1.925
Authors: A Giussani; M A Lopez; H Romm; A Testa; E A Ainsbury; M Degteva; S Della Monaca; G Etherington; P Fattibene; I Güclu; A Jaworska; D C Lloyd; I Malátová; S McComish; D Melo; J Osko; A Rojo; S Roch-Lefevre; L Roy; E Shishkina; N Sotnik; S Y Tolmachev; A Wieser; C Woda; M Youngman Journal: Radiat Environ Biophys Date: 2020-05-05 Impact factor: 1.925